Insulin Aspart vs Insulin Lispro is a comparison of two ultra-short-acting insulin. Both these insulins have been formulated further to very-rapid-acting insulins as well. “FiASP” is “faster Insulin Aspart) and Lispro-aabc or Insulin Lyumjev is the newly formulated Insulin Lispro.
All insulins have the same mechanism of action. They lower the blood glucose by enhancing the entry of glucose present in the plasma into the cells. The primary target cells for insulin to act are those of the skeletal muscles and the fat cells. Along with that, insulin also reduces hepatic glucose output and inhibits the breakdown of lipids and proteins.
All insulins when administered in doses exceeding the required dose can result in hypoglycemia. They may cause lipo-hypertrophy when administered repeatedly into one area. Some patients may also notice a hypersensitivity reaction to insulin or insulin analogs.
Insulin Lispro Vs Aspart – Comparing Pharmacokinetics:
|Newer Formulations||Insulin Lyumjev or Insulin Lispro-aabc||FiAsp (Faster Aspart)|
|Bioavailability||55% – 75%||80%|
|Half-Life:||One hour||70 – 80 minutes|
|The onset of action:||15 minutes||10 to 15 minutes|
|Duration of action:||Less than 5 hours||4 to 5 hours|
|Time to peak plasma concentration||One hour||40 – 50 minutes|
fiasp vs humalog
Insulin Lispro and Lispro-aabc Vs Aspart and FiAsp – Structural Differences:
Insulin Lispro is structurally different from human insulin as it has lysin instead of proline in position 28 and proline in position 29 instead of lysine in the Beta chains.
Insulin Lispro-aabc or Insulin Lyumjev is similar in structure to insulin Lispro, however, citrate and treprostinil are added to its structure that increases its absorption.
Insulin Aspart differs from human insulin as it has aspartic acid instead of proline at position B28.
Insulin FiAsp or Faster Aspart is similar to insulin Aspart except for the addition of niacinamide (vitamin B3) that enhances its absorption when it is administered subcutaneously.
Insulin Lispro vs Aspart – Which Insulin is more effective?
Insulin Lispro and Aspart are both rapid-acting insulins. Few clinical trials have directly compared Insulin Lispro and Aspart.
In a study conducted in patients with Type 1 Diabetes Mellitus, both insulin Lispro and Aspart resulted in similar insulin levels after 30 minutes of their administration, and the levels returned to baseline after 4 hours. There were no differences in the Plasma glucose levels, ketones, free fatty acids, and insulin requirements in patients receiving insulin Lispro or aspart [Ref].
Similar results were demonstrated in other studies as well. The pharmacodynamics and pharmacokinetic parameters of insulin Aspart and Lispro were found equivalent in both groups. Mean plasma glucose reduction, postprandial plasma glucose, and insulin requirements were similar in both groups.
Two patients in the insulin Aspart and five patients in the insulin Lispro developed hypoglycemia requiring glucose infusion. Statistical tests did not show any significant difference between the incidence of hypoglycemia in the two groups [Ref].
FiAsp Vs Aspart Insulin:
FiAsp is a modified form of Insulin Aspart. The addition of vitamin B3 to the structure of Insulin Aspart results in its rapid onset of action and rapid absorption via the skin when administered into the skin.
FiAsp was studied in comparison to Insulin Aspart in both T1DM and T2DM patients. Superior glycemic efficacy as measured by HbA1C and postmeal glucose was observed with FiAsp especially when both insulins were administered at mealtime or immediately after meals.
Both Insulin aspart and FiAsp had comparable side effects including the incidence of hypoglycemia.
Insulin Lispro Vs Insulin Lyumjev:
Similar results were observed in the Pronto-T1DM and Pronto-T2DM comparing Insulin Lyumjev (Insulin Lispro-aabc) with Insulin Lispro. Both insulins had a comparable safety profile and efficacy.
Insulin Lispro and Aspart have similar safety profiles and efficacies in achieving glycemic control. However, the newer formulation of Insulin Aspart (FiAsp) and Lispro (Lyumjev or Lispro-aabc) were observed to better control postmeal hyperglycemia.